Annual Report and Notice of AGM

RNS Number : 5585K

Alliance Pharma PLC

22 April 2020

 

22 April 2020

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

Annual Report & Accounts and Notice of AGM

Alliance Pharma plc (AIM: APH), the international healthcare group, announces that the following documents are now available on the Group's website, www.alliancepharmaceuticals.com :

· The Annual Report & Accounts for the year ended 31 December 2019

· The Notice of the 2020 Annual General Meeting ("AGM"), which will be held at 10.00am on 18 May 2020 a nd will be accessible to shareholders via a conference call facility, the dial-in details of which will be available ahead of the AGM

Printed copies of both documents have been posted to those shareholders who have opted out of receiving electronic communications from the Group.

Printed copies of the documents are also available by contacting Buchanan by email at [e-mail] or by telephoning Buchanan on 020 7466 5000.

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
Numis Securities Limited	+ 44 (0)20 7260 1000
Nominated Adviser: Freddie Barnfield / Huw Jeremy
Corporate Broking: James Black

Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website :  www.alliancepharmaceuticals.co m    

 

END

 

 

ACSUUVVRRSUSUAR